Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer

Davide Serrano, Laura Baglietto, Harriet Johansson, Frederique Mariette, Rosalba Torrisi, Marina Onetto, Michela Paganuzzi, Andrea Decensi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. Experimental Design: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. Results: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, -4.0 to 69.3) versus 5.1 (95% CI, -21.4 to 59.8) and -7.8 (95% CI, -18.2 to 52.5) versus -12.3 (95% CI, -44.6 to 9.6). However, in patients ages

Original languageEnglish
Pages (from-to)2083-2088
Number of pages6
JournalClinical Cancer Research
Volume11
Issue number5
DOIs
Publication statusPublished - Mar 1 2005

Fingerprint

Fenretinide
Insulin-Like Growth Factor Binding Protein 3
Retinoids
Prostate-Specific Antigen
Insulin-Like Growth Factor I
Urinary Bladder Neoplasms
Confidence Intervals
Prostatic Neoplasms
Research Design
Animal Models
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. / Serrano, Davide; Baglietto, Laura; Johansson, Harriet; Mariette, Frederique; Torrisi, Rosalba; Onetto, Marina; Paganuzzi, Michela; Decensi, Andrea.

In: Clinical Cancer Research, Vol. 11, No. 5, 01.03.2005, p. 2083-2088.

Research output: Contribution to journalArticle

@article{e9d887014ce245f184fe698cc004d054,
title = "Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer",
abstract = "Purpose: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. Experimental Design: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. Results: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95{\%} CI)] change for {\%} free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95{\%} CI, -4.0 to 69.3) versus 5.1 (95{\%} CI, -21.4 to 59.8) and -7.8 (95{\%} CI, -18.2 to 52.5) versus -12.3 (95{\%} CI, -44.6 to 9.6). However, in patients ages",
author = "Davide Serrano and Laura Baglietto and Harriet Johansson and Frederique Mariette and Rosalba Torrisi and Marina Onetto and Michela Paganuzzi and Andrea Decensi",
year = "2005",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-04-1549",
language = "English",
volume = "11",
pages = "2083--2088",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer

AU - Serrano, Davide

AU - Baglietto, Laura

AU - Johansson, Harriet

AU - Mariette, Frederique

AU - Torrisi, Rosalba

AU - Onetto, Marina

AU - Paganuzzi, Michela

AU - Decensi, Andrea

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Purpose: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. Experimental Design: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. Results: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, -4.0 to 69.3) versus 5.1 (95% CI, -21.4 to 59.8) and -7.8 (95% CI, -18.2 to 52.5) versus -12.3 (95% CI, -44.6 to 9.6). However, in patients ages

AB - Purpose: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. Experimental Design: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. Results: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, -4.0 to 69.3) versus 5.1 (95% CI, -21.4 to 59.8) and -7.8 (95% CI, -18.2 to 52.5) versus -12.3 (95% CI, -44.6 to 9.6). However, in patients ages

UR - http://www.scopus.com/inward/record.url?scp=16344371373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344371373&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1549

DO - 10.1158/1078-0432.CCR-04-1549

M3 - Article

VL - 11

SP - 2083

EP - 2088

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -